Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Sponsor: Shanghai Jiatan Pharmatech Co., Ltd
Summary
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced solid tumors. The main questions it aims to answer are: * the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of WX390; * safety and preliminary in combined therapy. Participants will be treated with WX390 orally and Toripalimab intravenously, and follow the efficacy and safety evaluation according to the protocol.
Official title: A Phase Ib/IIa Study to Evaluate the Safety and Preliminary Efficacy of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2022-11-18
Completion Date
2025-11-09
Last Updated
2024-11-25
Healthy Volunteers
No
Conditions
Interventions
WX390
WX390 tablet, once a day
Toripalimab
240 mg, Day 1, every 3 weeks
Locations (1)
the first affiliated hospital of Jilin university
Changchun, Jilin, China